Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Homology Medicines, Inc. (FIXX)

1.55   -0.07 (-4.32%) 11-25 13:00
Open: 1.59 Pre. Close: 1.62
High: 1.64 Low: 1.52
Volume: 177,705 Market Cap: 89(M)

Technical analysis

as of: 2022-11-25 1:57:03 PM
Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.23     One year: 2.67
Support: Support1: 1.29    Support2: 1.08
Resistance: Resistance1: 1.91    Resistance2: 2.28
Pivot: 1.63
Moving Average: MA(5): 1.71     MA(20): 1.59
MA(100): 1.99     MA(250): 2.5
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 36     %D(3): 42.4
RSI: RSI(14): 46.5
52-week: High: 5.14  Low: 1.29
Average Vol(K): 3-Month: 195 (K)  10-Days: 261 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ FIXX ] has closed above bottom band by 40.3%. Bollinger Bands are 35.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.82 - 1.83 1.83 - 1.83
Low: 1.52 - 1.54 1.54 - 1.55
Close: 1.6 - 1.62 1.62 - 1.64

Company Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Headline News

Wed, 23 Nov 2022
Tune In and Turn It Up: Here's Where to Find the Hottest Hits in Positive Hip-Hop - City-sentinel

Wed, 23 Nov 2022
Homology Medicines' (FIXX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Sat, 19 Nov 2022
FIXX, Catherine "Kitty" Pricilla - Santa Barbara News-Press

Fri, 18 Nov 2022
Oberlin Alum Jim Fixx OC '57: Forgotten Father Of Running - The Oberlin Review

Wed, 16 Nov 2022
Healthcare Stocks Moving Wednesday: INM, ENSC, FIXX, XGN, BKD, PEAR, PALI, NBY - InvestorsObserver

Sun, 13 Nov 2022
Holy Culture Radio's 'Da Fixx' Morning Show Wins Kingdom Choice Award - City-sentinel

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 57 (M)
% Held by Insiders 3.627e+007 (%)
% Held by Institutions 9.1 (%)
Shares Short 1,370 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.2934e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) -133.9
Operating Margin (%) -4
Return on Assets (ttm) 127.5
Return on Equity (ttm) -33.6
Qtrly Rev. Growth 3.21e+006
Gross Profit (p.s.) -1.04
Sales Per Share 0.59
EBITDA (p.s.) -1.54
Qtrly Earnings Growth -0.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -117 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 21.3
Price to Book value 0
Price to Sales 2.6
Price to Cash Flow -0.09

Stock Dividends

Dividend 0
Forward Dividend 1.12e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.